SPRB
Spruce Biosciences, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
51.58
▼ 0.41 (0.78%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
52.00
Prev close
51.99
Day high
53.00
Day low
49.03
Volume
62.31K
Market cap
$148.24M
P/E (TTM)
—
52W range
7.00 – 240.00
Day trading desk
Gap from prior close
+0.03%
Prior close 51.99
VWAP
51.00
+1.13% from price
Relative volume
0.98×
Normal
Session range
8.10%
49.03 – 53.00
Position in range
64%
Mid range
ATR (14D)
2.86
5.55% of price
Prior day high
52.89
PDH
Prior day low
50.50
PDL
Bid / ask spread
—
Quote not published
Session volume
62.40K
Avg 63.55K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-2.01%
-0.6%
1M
+14.65%
+10.9%
3M
-2.13%
-5.2%
6M
+3.74%
-7.3%
YTD
-40.79%
-53.1%
1Y
+516.25%
+496.3%
3Y
-99.59%
-173.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on SPRB open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
96.97K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 30, 26 | SZWARCBERG JAVIER B M.D. Chief Executive Officer |
STOCK | 266 | $14.36K | Direct |
| Dec 31, 25 | SZWARCBERG JAVIER B M.D. Chief Executive Officer |
STOCK | 4.69K | $408.55K | Direct |
| Dec 15, 25 | GHARIB SAMIR M President |
— | 1.01K | — | Direct |
| Dec 15, 25 | SZWARCBERG JAVIER B M.D. Chief Executive Officer |
— | 2.68K | — | Direct |
| Dec 11, 25 | GHARIB SAMIR M President |
— | 2.41K | — | Direct |
| Dec 11, 25 | WAYS DOUGLAS KIRK M.D., PH.D. Officer and Director |
— | 1.25K | — | Direct |
| Dec 11, 25 | SZWARCBERG JAVIER B M.D. Chief Executive Officer |
— | 6.15K | — | Direct |
| Oct 20, 25 | GHARIB SAMIR M President |
— | 2.05K | — | Direct |
| Oct 20, 25 | SZWARCBERG JAVIER B M.D. Chief Executive Officer |
— | 4.78K | — | Direct |
| Oct 6, 25 | PARKMAN HEALTHCARE PARTNERS LLC Beneficial Owner of more than 10% of a Class of Security |
SELL | 257 | $33.51K | Indirect |
| Oct 6, 25 | PARKMAN HEALTHCARE PARTNERS LLC Beneficial Owner of more than 10% of a Class of Security |
SELL | 257 | $33.51K | Indirect |
| Oct 6, 25 | PARKMAN HEALTHCARE PARTNERS LLC Beneficial Owner of more than 10% of a Class of Security |
BUY | 256 | $33.38K | Indirect |
| Oct 6, 25 | PARKMAN HEALTHCARE PARTNERS LLC Beneficial Owner of more than 10% of a Class of Security |
BUY | 256 | $33.38K | Indirect |
| Dec 16, 24 | GHARIB SAMIR M President |
— | 229.75K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CHARLTON RALPH WILLIAM III |
Officer | 161.34K | Conversion of Exercise of derivative security |
GHARIB SAMIR M |
President | 8.26K | Conversion of Exercise of derivative security |
PARKMAN HEALTHCARE PARTNERS LLC |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
SZWARCBERG JAVIER B M.D. |
Chief Executive Officer | 19.27K | Stock Award(Grant) |
WAYS DOUGLAS KIRK M.D., PH.D. |
Officer and Director | 1.25K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$148.24M
Enterprise value$59.62M
Revenue (TTM)—
Gross profit$-22.95M
EBITDA$-39.04M
Net income$-51.35M
EPS (TTM)$-38.43
Free cash flow$-20.65M
Total cash$96.30M
Total debt$7.67M
Book value / share$25.25
Shares outstanding2.87M
Float2.02M
Short % of float15.75%
Dividend yield—
Beta (5Y)3.34
Valuation & profitability ratios
Trailing P/E—
Forward P/E6.37
PEG ratio—
Price / sales—
Price / book2.04
EV / revenue—
EV / EBITDA-1.53
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-105.98%
Return on assets-40.03%
Debt / equity9.16
Current ratio9.23
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $4.91M | $10.09M | $0 | -100.0% |
| Operating revenue | $0 | $4.91M | $10.09M | $0 | -100.0% |
| Research & development | $19.52M | $46.42M | $49.43M | $35.20M | -57.9% |
| Selling, general & admin | $16.99M | $14.64M | $12.65M | $12.09M | +16.0% |
| Total operating expense | $36.51M | $61.06M | $62.08M | $47.28M | -40.2% |
| Operating income | -$36.51M | -$56.15M | -$51.99M | -$47.28M | +35.0% |
| Net interest income | $1.05M | $3.12M | $4.07M | $1.10M | -66.4% |
| Pre-tax income | -$38.97M | -$53.04M | -$47.92M | -$46.18M | +26.5% |
| Net income | -$38.97M | -$53.04M | -$47.92M | -$46.18M | +26.5% |
| Net income to common | -$38.97M | -$53.04M | -$47.92M | -$46.18M | +26.5% |
| Basic EPS | -50.83 | -96.40 | -93.00 | -147.00 | +47.3% |
| Diluted EPS | -50.83 | -96.40 | -93.00 | -147.00 | +47.3% |
| EBIT | -$38.88M | -$52.73M | -$47.44M | -$45.76M | +26.3% |
| EBITDA | -$38.85M | -$52.68M | -$47.37M | -$45.69M | +26.2% |
| Basic shares | 766.60K | 550.15K | 513.47K | 313.69K | +39.3% |
| Diluted shares | 766.60K | 550.15K | 513.47K | 313.69K | +39.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $48.91M | $38.75M | $96.34M | $24.49M | — | +26.2% |
| Cash & short-term investments | $48.91M | $38.75M | $96.34M | $79.08M | — | +26.2% |
| Total current assets | $52.11M | $44.21M | $102.18M | $83.61M | — | +17.9% |
| Property, plant & equipment | $666.00K | $934.00K | $1.18M | $1.40M | — | -28.7% |
| Total assets | $53.02M | $45.21M | $103.95M | $85.65M | — | +17.3% |
| Total current liabilities | $10.09M | $15.25M | $24.46M | $12.45M | — | -33.8% |
| Current debt | — | $1.62M | $1.62M | $1.62M | — | — |
| Long-term debt | — | $124.00K | $1.72M | $3.29M | $4.88M | — |
| Total debt | $736.00K | $2.77M | $4.61M | $6.32M | — | -73.4% |
| Total liabilities | $10.51M | $16.39M | $27.44M | $17.16M | — | -35.9% |
| Retained earnings | -$289.23M | -$250.27M | -$197.23M | -$149.31M | — | -15.6% |
| Shareholder equity | $42.52M | $28.82M | $76.51M | $68.49M | — | +47.5% |
| Working capital | $42.03M | $28.96M | $77.72M | $71.16M | — | +45.1% |
| Net tangible assets | $42.52M | $28.82M | $76.51M | $68.49M | — | +47.5% |
| Shares issued | 1.37M | 563.08K | 547.06K | 314.68K | — | +143.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$38.97M | -$53.04M | -$47.92M | -$46.18M | — | +26.5% |
| Depreciation & amortisation | $21.00K | $46.00K | $70.00K | $74.00K | — | -54.3% |
| Stock-based compensation | $2.57M | $5.35M | $4.62M | $3.63M | — | -51.9% |
| Change in working capital | -$724.00K | -$8.57M | $10.36M | $1.13M | — | +91.6% |
| Operating cash flow | -$33.33M | -$55.96M | -$33.27M | -$41.68M | — | +40.4% |
| Capital expenditure | — | — | -$7.00K | -$8.00K | -$93.00K | — |
| Investing cash flow | — | $0 | $55.78M | $23.69M | -$79.17M | — |
| Financing cash flow | $43.48M | -$1.62M | $49.14M | -$241.00K | — | +2,780.7% |
| Free cash flow | -$33.33M | -$55.96M | -$33.28M | -$41.69M | — | +40.4% |
| End cash position | $48.94M | $38.79M | $96.37M | $24.73M | — | +26.2% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $7.58M | $4.10M | $5.01M | — | $10.84M | $21.46M | +84.6% |
| Selling, general & admin | $4.41M | $7.00M | $3.22M | $3.12M | $3.65M | — | -36.9% |
| Total operating expense | $11.99M | $11.10M | $8.23M | $2.69M | $14.49M | — | +8.0% |
| Operating income | -$11.99M | -$11.10M | -$8.23M | -$2.69M | -$14.49M | — | -8.0% |
| Net interest income | -$188.00K | -$46.00K | $17.00K | $625.00K | $293.00K | — | -308.7% |
| Pre-tax income | -$12.27M | -$14.65M | -$8.21M | -$2.07M | -$14.04M | — | +16.3% |
| Net income | -$12.27M | -$14.65M | -$8.21M | -$2.07M | -$14.04M | — | +16.3% |
| Net income to common | -$12.27M | -$14.65M | -$8.21M | -$2.07M | -$14.04M | — | +16.3% |
| Basic EPS | -8.94 | — | -14.58 | -3.49 | -23.95 | — | — |
| Diluted EPS | -8.94 | — | -14.58 | -3.49 | -23.95 | — | — |
| EBIT | -$11.59M | -$14.64M | -$8.19M | -$2.04M | -$14.01M | — | +20.8% |
| EBITDA | -$11.34M | -$14.63M | -$8.19M | -$2.03M | -$14.00M | — | +22.5% |
| Basic shares | 1.37M | — | 563.07K | 592.62K | 586.14K | — | — |
| Diluted shares | 1.37M | — | 563.07K | 592.62K | 586.14K | — | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $54.08M | $48.91M | $10.67M | $16.39M | $25.61M | — | +10.6% |
| Cash & short-term investments | $54.08M | $48.91M | $10.67M | $16.39M | $25.61M | — | +10.6% |
| Total current assets | $55.03M | $52.11M | $14.52M | $20.95M | $30.58M | — | +5.6% |
| Property, plant & equipment | $595.00K | $666.00K | $735.00K | $803.00K | $869.00K | — | -10.7% |
| Total assets | $56.17M | $53.02M | $15.31M | $21.82M | $31.65M | — | +5.9% |
| Total current liabilities | $11.78M | $10.09M | $9.43M | $8.06M | $15.67M | — | +16.8% |
| Current debt | $1.00M | — | $539.00K | $943.00K | $1.34M | $1.62M | — |
| Long-term debt | $5.46M | — | — | — | — | $124.00K | — |
| Total debt | $7.12M | $736.00K | $1.35M | $1.82M | $2.29M | — | +867.7% |
| Total liabilities | $21.52M | $10.51M | $9.93M | $8.64M | $16.32M | — | +104.8% |
| Retained earnings | -$301.50M | -$289.23M | -$274.59M | -$266.38M | -$264.31M | — | -4.2% |
| Shareholder equity | $34.65M | $42.52M | $5.39M | $13.18M | $15.32M | — | -18.5% |
| Working capital | $43.25M | $42.03M | $5.09M | $12.89M | $14.91M | — | +2.9% |
| Net tangible assets | $34.65M | $42.52M | $5.39M | $13.18M | $15.32M | — | -18.5% |
| Shares issued | 1.37M | 1.37M | 563.49K | 563.04K | 563.08K | — | +0.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$12.27M | -$14.65M | -$8.21M | -$2.07M | -$14.04M | — | +16.3% |
| Depreciation & amortisation | $252.00K | $5.00K | $3.00K | $7.00K | $6.00K | — | +4,940.0% |
| Stock-based compensation | $689.00K | $1.69M | $415.00K | -$77.00K | $544.00K | — | -59.3% |
| Change in working capital | $2.43M | $2.41M | $2.31M | -$6.30M | $857.00K | — | +1.0% |
| Operating cash flow | -$8.73M | -$6.46M | -$5.32M | -$8.83M | -$12.73M | — | -35.3% |
| Capital expenditure | -$10.00K | — | — | — | — | — | — |
| Investing cash flow | -$10.00K | — | — | — | $0 | $0 | — |
| Financing cash flow | $13.92M | $44.69M | -$402.00K | -$400.00K | -$411.00K | — | -68.9% |
| Free cash flow | -$8.74M | -$6.46M | -$5.32M | -$8.83M | -$12.73M | — | -35.4% |
| End cash position | $54.12M | $48.94M | $10.70M | $16.42M | $25.65M | — | +10.6% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -6.12 | -6.68 | -9.1% |
| Mar 2026 | -6.12 | -8.94 | -46.2% |
| Dec 2025 | -9.57 | -9.58 | -0.2% |
| Sep 2025 | -12.31 | -14.58 | -18.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -5.79 | 6 | $0 | 0.0% |
| Next quarter | -5.80 | 6 | $0 | 0.0% |
| Current year | -27.16 | 6 | $0 | 0.0% |
| Next year | 8.09 | 7 | $88.56M | 0.0% |
Analyst targets & ownership
Mean target$147.88
High target$230.00
Low target$104.00
Implied upside186.69%
Analyst count8
ConsensusSTRONG BUY
Strong buy / Buy1 / 7
Hold0
Sell / Strong sell0 / 0
Held by insiders3.37%
Held by institutions76.64%
Institutions holding91
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
50.44
+2.26% from price
SMA 20
47.25
+9.17% from price
SMA 50
48.61
+6.10% from price
SMA 100
52.87
-2.43% from price
SMA 200
66.30
-22.20% from price
EMA 12
50.16
+2.83% from price
EMA 26
48.71
+5.89% from price
EMA 50
49.31
+4.60% from price
RSI (14)
61.5
Neutral
MACD (12,26,9)
1.45
Hist 0.83
ATR (14)
2.86
5.55% of price
Realised vol 30D
44.1%
Annualised
Bollinger upper
55.26
20, 2σ
Bollinger lower
39.23
20, 2σ
50 / 200 cross
Death
48.61 vs 66.30
Trend bias
Below 200
-22.20%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
3.53
More volatile than market
Correlation to SPY
0.03
Largely independent
Realised vol 30D
44.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-77.3%
Peak to trough
Max drawdown 5Y
-100.0%
Peak to trough
ATR 14
2.86
5.55% of price
Beta (reported)
3.34
5Y monthly, from filing
Short interest
Shares short
429.12K
Prior 359.39K
Change vs prior
+19.4%
Shorts adding
% of float
15.75%
Elevated
% of shares out
15.59%
Against total outstanding
Days to cover
6.7
Crowded exit
Float
2.02M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 17, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Aug 13, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Jul 13, 26 | B. Riley Securities | INITIATED | — | Buy |
| Jun 16, 26 | Guggenheim | INITIATED | — | Buy |
| Jun 9, 26 | Jones Trading | INITIATED | — | Buy |
| Jun 1, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 14, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Apr 27, 26 | Craig-Hallum | INITIATED | — | Buy |
| Mar 10, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Mar 10, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 19, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 23, 25 | Oppenheimer | INITIATED | — | Outperform |
Dividends & splits
Forward rate—
Forward yield—
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:75
Split dateAug 7, 2025
SEC filings
Periodic Financial Reports
10-Q · 2026-08-12
Corporate Changes & Voting Matters
8-K · 2026-07-27
Corporate Changes & Voting Matters
8-K · 2026-05-26
Periodic Financial Reports
10-Q · 2026-05-13
Corporate Changes & Voting Matters
8-K · 2026-04-22
Proxy Statements
DEF 14A · 2026-04-09
Corporate Changes & Voting Matters
8-K · 2026-03-20
Corporate Changes & Voting Matters
8-K · 2026-02-05
Headlines
Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Business Wire · 11d ago
Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences
Business Wire · 11d ago
Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development
Business Wire · 20d ago
Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer
Business Wire · 27d ago
American Express, Biogen upgraded: Wall Street's top analyst calls
The Fly · 41d ago
B. Riley Initiates Spruce Biosciences at Buy With $160 Price Target
MT Newswires · 41d ago
Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
Business Wire · 46d ago
Spruce Biosciences Joins the Russell 3000® Index
Business Wire · 55d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.